Inspired by antibodies found in long-term leukemia survivors, a novel selective CAR T approach eliminated AML in preclinical ...
In fact, once Health Canada approves a drug, the process should skip Canada’s Drug Agency entirely. The CDA is a bureaucratic ...
The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...
A limitation to cancer treatment, specifically acute myeloid leukemia (AML) is the ability to effectively target tumors cells ...
FDA authorized decitabine/cedazuridine plus venetoclax as the first all-oral HMA/BCL-2 regimen for newly diagnosed AML patients unfit for intensive induction chemotherapy. ASCERTAIN-V enrolled 101 ...
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers and is characterized by the rapid growth of immature ...
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the ...
Now, after chemotherapy and a breakthrough treatment that required her to wear a backpack for months at time, Matilda rang ...
Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are ...
Relapse rates were significantly lower with letermovir despite comparable non-relapse mortality and incidence of GVHD.
Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results